GLP-1 Market
LLY $1152.44 ▲ +1.3% NVO $43.19 ▲ +3.5% PFE $27.64 ▲ +0.7% VKTX $29.36 ▼ -0.5% KLRA $12.92 ▲ +1.7% GPCR $35.10 ▼ -1.1% RHHBY $54.60 ▼ -1.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

High-Intensity Statin Therapy

Company
Taipei Medical University Hospital
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 18, 2026

Find a Clinical Trial Near Me

See recruiting studies for High-Intensity Statin Therapy and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06676280

    ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

    Not yet reported Jung-min Ahn 5000 participants Est. completion 2035-12-31 32 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Recruiting NCT NCT06767774

    Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus

    Not yet reported Korea University Anam Hospital 2000 participants Est. completion 2030-01-31 1 site
    Cardiovascular disease Other conditions: Diabetes, Statin
    View official trial listing →
  • Recruiting NCT NCT07012629

    A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)

    Not yet reported Aarhus University Hospital 1652 participants Est. completion 2040-01-01 14 sites Stand-alone
    Other conditions: Covert Brain Infarction
    View official trial listing →
  • Recruiting NCT NCT07611747

    Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)

    Not yet reported Instituto de Investigación Marqués de Valdecilla 1944 participants Est. completion 2031-12 17 sites Stand-alone
    Other conditions: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondy, Systemic Lupus Erythematosus (SLE), Caridovascular Disease, Atherosclerosis, Carotid Artery Diseases
    View official trial listing →
  • Recruiting NCT NCT07824323

    Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome

    Not yet reported Taipei Medical University Hospital 400 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Acute Coronary Syndromes, Dyslipidemia
    View official trial listing →
  • Status unknown NCT NCT02579499

    Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease

    Not yet reported Yonsei University 4400 participants Est. completion 2022-11 1 site
    Other conditions: Coronary Artery Diseasse
    View official trial listing →
  • Completed NCT NCT02586155

    Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

    Not yet reported Resverlogix Corp 2425 participants Est. completion 2021-06-21 214 sites Stand-alone
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT04753606

    Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

    Not yet reported NewAmsterdam Pharma 120 participants Est. completion 2021-08-30 19 sites
    Other conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT05166187

    Best Practice Advisory to Initiate High-Intensity Statin Therapy in Patients With Peripheral Artery Disease

    Not yet reported Vanderbilt University Medical Center 152 participants Est. completion 2023-11-13 1 site
    Other conditions: Peripheral Artery Disease
    View official trial listing →
  • Completed NCT NCT05266586

    Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

    Not yet reported NewAmsterdam Pharma 119 participants Est. completion 2022-09-08 16 sites
    Other conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT05306990

    Statins in Patients With Type 2 Diabetes Mellitus and Previous History of Acute Coronary Syndrome

    Not yet reported Helwan University 108 participants Est. completion 2021-01-31 1 site
    Other conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus
    View official trial listing →
  • Active, not recruiting NCT NCT05457582

    PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI

    Not yet reported Nanjing First Hospital, Nanjing Medical University 1212 participants Est. completion 2030-12-30 1 site
    Other conditions: Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention, Cardiovascular Events
    View official trial listing →
  • Enrolling by invitation NCT NCT05579626

    Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)

    Not yet reported Seung-Whan Lee, M.D., Ph.D. 4000 participants Est. completion 2030-12-31 31 sites
    Cardiovascular disease Other conditions: Pre Diabetes
    View official trial listing →
  • Completed NCT NCT05806723

    Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men

    Not yet reported Hopital La Rabta 104 participants Est. completion 2022-09-15 1 site
    Type 2 diabetes Other conditions: Dyslipidemia Associated With Type II Diabetes Mellitus, Statin Adverse Reaction, Hypogonadism, Male, Adrenal Insufficiency, Vitamin D Deficiency
    View official trial listing →
  • Active, not recruiting NCT NCT06238466

    A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

    Not yet reported AstraZeneca 98 participants Est. completion 2027-04-08 5 sites
    Other conditions: Cardiovascular
    View official trial listing →
  • Not yet recruiting NCT NCT07432516

    Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial

    Not yet reported Yonsei University 4400 participants Est. completion 2033-06 1 site
    Cardiovascular disease
    View official trial listing →
  • Not yet recruiting NCT NCT07586540

    Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque

    Not yet reported Middle East North Africa Stroke and Interventional Neurotherapies Organization 280 participants Est. completion 2030-09 14 sites Stand-alone
    Other conditions: Carotid Stenosis
    View official trial listing →
  • Not yet recruiting NCT NCT07799779

    Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome

    Not yet reported Seoul National University Bundang Hospital 294 participants Est. completion 2029-09 1 site Stand-alone
    Other conditions: Acute Coronary Syndromes (ACS)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.